Fig. 1: A flowchart diagram summarising the investigation pathway of 65 study participants with a new diagnosis of neovascular age-related macular degeneration (AMD).

Peripheral blood samples were taken at seven visits (baseline visit and six follow-up visits), for serum and genotypic analysis.